ESMO 2024 | PRS as predictors of endocrine toxicities in checkpoint inhibitor therapy
Christian Thorball, PhD, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, discusses how polygenic risk scores (PRS) can help predict persistent checkpoint inhibitor-related endocrine toxicities such as thyroid dysfunction, hypophysitis, and diabetes. These toxicities are particularly relevant in curative settings, as they often require lifelong management post-treatment. Genetic predispositions may help in forecasting endocrine risks, allowing clinicians to better anticipate and manage these long-term effects in patients undergoing immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
